Home » Table of Content » First report of treatment failure in a patient with cutaneous leishmaniasis infected by Leishmania (Viannia) naiffi carrying Leishmania RNA virus: a fortuitous combination?

First report of treatment failure in a patient with cutaneous leishmaniasis infected by Leishmania (Viannia) naiffi carrying Leishmania RNA virus: a fortuitous combination?

Ricardo Vieira-Gonçalves1 # Giselle Aparecida Fagundes-Silva1 # Júlia Furtado Heringer1 Maria Fantinatti1 Alda Maria Da-Cruz1 Manoel Paes Oliveira-Neto2 Jorge Augusto Oliveira Guerra3 Adriano Gomes-Silva1 4

1Laboratório Interdisciplinar de Pesquisas Médicas, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brasil. 2Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, RJ, Brasil. 3Gerência de Leishmaniose, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, AM, Brasil. 4Laboratório de Pesquisa Clínica em Micobacterioses, Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, RJ, Brasil.

DOI: 10.1590/0037-8682-0323-2018


ABSTRACT

We report the case of a 32-year-old man from Rio de Janeiro, who was infected in the Amazon region of Brazil by Leishmania (Viannia) naiffi. Generally, patients with L. naiffi cutaneous leishmaniasis exhibit a good therapeutic response to either pentavalent antimonials or pentamidine. However, after pentamidine treatment, this patient’s infection evolved to therapeutic failure. To understand this clinical outcome, we investigated the presence of the Leishmania RNA virus (LRV) in parasites isolated from the cutaneous lesion; herein, we discuss the possible association between a poor response to pentamidine therapy and the presence of the LRV.

Keywords: Leishmania (Viannia) naiffi; Therapeutic failure; Leishmania RNA virus

INTRODUCTION

Leishmania (Viannia) naiffi was first isolated in the armadillo (Dasypus novemcinctus) in 1989 by Lainson and Shaw in the Brazilian Amazon1. Soon after, this species was detected in a patient with human cutaneous leishmaniasis (CL). Other cases were reported in Latin America2, most of which involved military personnel or tourists3. However, L. naiffi is still considered an unusual parasite species. In Brazil, these cases occur mainly in the Amazon region, where frequencies of 4%, 20%, or even 26.7%4have been reported.

L. naiffi CL lesions are usually ulcerated, unique, and small, located on the hands, arms, or legs. They usually develop with a favorable prognosis and even spontaneous healing3, and mucosal leishmaniasis has not yet been reported. Commonly, patients with L. naiffi CL exhibit a good therapeutic response to either pentavalent antimonials or pentamidine2. In addition, experimental studies have shown that L. naifficauses discrete or even unapparent infections on the skin of hamsters1.

We describe an unusual L. naiffi CL case that evolved with pentamidine resistance, and we also discuss the possible association between poor therapy response and the presence of the Leishmania RNA virus (LRV).

CASE REPORT

A 32-year-old man from Rio de Janeiro state, Brazil, was infected in September 2009 during his military training in the Amazon region (Manaus, AM). A papular lesion approximately 0.5 cm in diameter was noted on his left hand 30 days later. No lymphadenopathy was detected. The patient was treated with a three-day course of pentamidine (4 mg/kg). The treatment was unsuccessful, and an active lesion persisted (Figure 1A). In March 2010, the patient underwent surgical removal of the entire lesion. Pseudo-epitheliomatous squamous hyperplasia and chronic granulomatous dermatitis were observed on histopathological analysis. No amastigotes were found. Leishmania spp. was isolated and characterized as L. naiffi based on isoenzyme electrophoresis. One month after the surgical procedure and without undergoing another round of therapy, no signs of active disease were detected. The scar remained completely healed until three years after surgery (Figure 1B and 1C), at which time clinical follow-up was discontinued.

Anti-Leishmania immunoglobulin G (IgG), IgG1, and IgG3 were measured using the enzyme-linked immunosorbent assay method. Despite therapeutic failure, immunoglobulin levels remained negative up to two years after treatment. The LRV was detected in the sample using a sequencing technique (Figure 1D). The LRV from L. naiffi showed 91% identicality with LRV1 sequences from GenBank.

FIGURE 1: Leishmania (Viannia) naiffi cutaneous leishmaniasis lesion on the patient’s hand after pentamidine therapy failure (A) and progressive healing after its surgical removal (scar at one “B” and three years “C” after surgical removal). (D) The alignment of Leishmania RNA virus (LRV) sequences from L. naiffi isolated from CL patient with the LRV1 sequences from GenBank showed 91% identicality. LRV cDNA was amplified using previously described primers6, and the PCR products were sequenced using the ABI PrismTM BigDye Terminator Cycle Sequencing Kit and run on an ABI 3730 automatic DNA sequencer (Applied Biosystems, Foster City, CA). The electropherograms were analyzed using Chromas software and the consensus DNA sequence compared was generated by the CAP3 program. The contig was aligned with known LRV sequences obtained from Genbank using the ClustalW algorithm in MEGA version 4.0. 

DISCUSSION

This case involved therapeutic pentamidine failure in CL caused by L. naiffi, and it is intriguing that complete cure was achieved after surgical removal of the lesion. Two possible hypotheses to explain this therapeutic failure occurrence are as follows: 1) therapeutic failure in L. naiffi CL is a more common phenomenon than previously reported and 2) the presence of the LRV contributed to increased parasite virulence.

The frequency of human L. naiffi infection is likely underreported due to the failure of health systems to isolate and identify Leishmania species. Recent reports suggest that transmission of L. naiffi in the Amazon region may be more common than expected4. Furthermore, we described another two of eight cases of L. naiffi infection that evolved with therapeutic failure post-pentamidine or -antimony treatment4. However, the mechanisms associated with L. naiffi resistance to these drugs are unknown.

The LRV has primarily been detected in two Viannia subgenera (L. braziliensis and L. guyanensis species), and its role as a virulence factor remains controversial. Indeed, studies have suggested that the LRV reduces sensitivity to oxidative stress, which may contribute to the decreased effectiveness of drugs5. Furthermore, this double-stranded RNA virus is known to increase the transcription of proinflammatory cytokines6, which in turn promotes tissue damage and poor prognosis. Remarkably, we first evidenced the presence of the LRV in L. naiffi species, raising the possibility that the presence of this virus could increase Leishmania spp. virulence and thereby influence therapeutic failure. Case studies of CL caused by L. braziliensis7 or L. guyanensis8 revealed that treatment failure with antimonial therapy or pentamidine, respectively, was significantly higher when an isolated parasite presents with the LRV infection. Further studies are needed to confirm its role in the dynamics of Leishmania spp. infection.

This study reinforces the importance of defining the true epidemiological importance of L. naiffi as an etiological agent of CL in South America, especially in the Amazon region. Thus, the identification of possible factors associated with treatment failure should allow for better clinical monitoring of patients.

ACKNOWLEDGMENTS

The authors thank the technical team from “Gerência de Leishmaniose – Fundação de Medicina Tropical Heitor Vieira Dourado.” We also thank the “Laboratório de Referência Nacional para Tipagem de Leishmania” (IOC), FIOCRUZ, and the sequencing platform (IOC).

REFERENCES

1. Lainson R, Shaw JJ. Leishmania (Viannia) naiffi sp. n., a parasite of the armadillo, Dasypus novemcinctus (L.) in Amazonian Brazil. Ann Parasitol Hum Comp. 1989;64(1):3-9. [ Links ]

2. Pratlong F, Deniau M, Darie H, Eichenlaub S, Pröll S, Garrabe E, et al. Human cutaneous leishmaniasis caused by Leishmania naiffi is wide-spread in South America. Ann Trop Med Parasitol. 2002;96(8):781-5. [ Links ]

3. van der Snoek EM, Lammers AM, Kortbeek LM, Roelfsema JH, Bart A, Jaspers CA. Spontaneous cure of American cutaneous leishmaniasis due to Leishmania naiffi in two Dutch infantry soldiers. Clin Exp Dermatol. 2009;34(8):e889-91. [ Links ]

4. Fagundes-Silva GA, Romero GA, Cupolillo E, Yamashita EP, Gomes-Silva A, Guerra JA. Leishmania (Viannia) naiffi: rare enough to be neglected? Mem Inst Oswaldo Cruz. 2015;110(6):797-800. [ Links ]

5. Hartley MA, Ronet C, Zangger H, Beverley SM, Fasel N. Leishmania RNA virus: when the host pays the toll. Front Cell Infect Microbiol. 2012;2:99. [ Links ]

6. Ives A, Ronet C, Prevel F, Ruzzante G, Fuertes-Marraco S, Schutz F, et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science. 2011;11(6018):775-8. [ Links ]

7. Adaui V, Lye LF, Akopyants NS, Zimic M, Llanos-Cuentas A, Garcia L, et al. Association of the endobiont double-stranded RNA virus LRV1 with treatment failure for human leishmaniasis caused by Leishmania braziliensis in Peru and Bolivia. J Infect Dis. 2016;213(1):112-21. [ Links ]

8. Bourreau E, Ginouves M, Prévot G, Hartley MA, Gangneux JP, Robert-Gangneux F, et al. Presence of Leishmania RNA virus 1 in Leishmania guyanensisincreases the risk of first-line treatment failure and symptomatic relapse. J Infect Dis . 2016;213(1):105-11. [ Links ]

Financial Support: This work was funded by Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ-APQ1) (grant number E-26/110.497/2012) (www.faperj.br), and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (number 458858/2014-5). AMDC is a CNPq and FAPERJ (CNE) research fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Received: August 16, 2018; Accepted: December 17, 2018

Corresponding author: Dr. Adriano Gomes-Silva. e-mail:adriano.gomes@ini.fiocruz.br

#Both authors contributed equally to this work.

Conflict of Interest: The authors declare that there is no conflict of interest.